ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ExpreS2ion Biotech Holding AB's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

ExpreS2ion Biotech Holding AB's long-term debt to total assets ratio declined from Dec. 2023 (0.02) to Dec. 2024 (0.00). It may suggest that ExpreS2ion Biotech Holding AB is progressively becoming less dependent on debt to grow their business.

ExpreS2ion Biotech Holding AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for ExpreS2ion Biotech Holding AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ExpreS2ion Biotech Holding AB LT-Debt-to-Total-Asset Chart

ExpreS2ion Biotech Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

ExpreS2ion Biotech Holding AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	-	-	-	-

ExpreS2ion Biotech Holding AB LT-Debt-to-Total-Asset Calculation

ExpreS2ion Biotech Holding AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0	/	104.531
	=	0.00

ExpreS2ion Biotech Holding AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0	/	104.531
	=	0.00

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ExpreS2ion Biotech Holding AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ExpreS2ion Biotech Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25

Website

https://www.expres2ionbio.com

ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB Headlines

No Headlines